Exploratory study of CL2020 in ST-elevation acute myocardial infarction

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080223778

Enrollment

Registered

2018-01-16

Start date

2018-03-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ST-elevation myocardial infarction

Interventions

investigational material(s) Generic name etc : CL2020 INN of investigational material : Therapeutic category code : 49- Other agents affecting cellular function Dosage and Administration for Investig

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with ST-elevation acute myocardial infarction with successful reperfusion by PCI etc.

Exclusion criteria

Exclusion criteria: -Previous myocardial infarction -Cardiogenic shock -Cerebral vascular disease (cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, etc.) or transient ischemic attach within 3 months

Design outcomes

Primary

Measure	Time frame
safety Safety of CL2020	—

Secondary

Measure	Time frame
efficacy Efficacy of CL2020 on cardiac function, etc.	—

Countries

Japan

Contacts

Public Contactcall center

Life Science Institute Inc.

lsii.chiken-inq@eppharmaline.co.jp+81-3-6748-7200

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026